16 October 2024 US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity.
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Mid-sized French drugmaker Ipsen today revealed the appointment of Christelle Huguet as executive vice president, head of research and development. 4 September 2023
The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) recommends new measures to avoid exposure of children to topiramate-containing medicines in the womb, because the medicine may increase the risk of neurodevelopmental problems after exposure during pregnancy. 4 September 2023
Germany has some strengths to show in the competition among locations for pharmaceutical R&D, but has nevertheless been falling behind internationally for some years, for example in the area of clinical trials, according to a posting on the web site of the German pharma trade group the vfa. 4 September 2023
Reeling from a regulatory setback last month, Sage Therapeutics is to undergo a major restructuring in the run-up to its launch of postpartum depression drug Zurzuvae (zuranolone). 1 September 2023
The combination of mezigdomide and dexamethasone exhibited activity among patients with heavily pre-treated multiple myeloma (MM), according to Phase I/II trial results published in The New England Journal of Medicine. 1 September 2023
Ireland-headquartered Ovoca Bio saw its shares plunge 82% to 2.50 pence yesterday, after it revealed disappointing results from a Phase II dose ranging study assessing orenetide conducted in Australia and New Zealand. 1 September 2023
Japanese mid-size drugmaker Otsuka Pharmaceuticals has entered into a definitive arrangement agreement to acquire Toronto, Canada-based Mindset Pharma. 1 September 2023
Privately-held Danish company MC2 Therapeutics today announced an agreement under which a Huadong Medicine unit has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream for the treatment of plaque psoriasis. 31 August 2023
French drugmaker Sanofi has made a series of changes to its executive team, including the appointment of a new head of research and development. 31 August 2023
US pharma giant Merck & Co, known as MSD outside of the USA and Canada, will stop deliveries to Russia of Zepatier (elbasvir/grazoprevir), one of the most popular drugs against hepatitis C, reports The Pharma Letter’s local correspondent. 30 August 2023
In a bid to consolidate its lead in the weight management therapy sector, diabetes care giant Novo Nordisk has now bought a fellow Denmark based company and its obesity program. 30 August 2023
Japanese drugmaker Kyowa Kirin has received approval in its home country for a higher-dose formulation of its oral calcimimetics agent Orkedia (evocalcet). 30 August 2023
Japanese drugmaker Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, has announced that its FGFR inhibitor Lytgobi (futibatinib) has now been listed on the National Health Insurance (NHI) reimbursement price list. 30 August 2023
Following the US Food and Drug Administration’s (FDA) recent approval of US healthcare giant Johnson & Johnson’s Akeega, the fixed dose combination of niraparib and abiraterone acetate with prednisone for a new indication, analysts at GlobalData have reviewed the drug’s prospects and challenges. 30 August 2023
Notwithstanding what it called “positive” late-stage trials with its acoramidis over the weekend, BridgeBio Pharma saw its shares fall almost 4.5% to $28.36 in early trading on Monday. 29 August 2023
Today, the US Centers for Medicare & Medicaid Services (CMS) has for the first time selected 10 drugs for negotiation. Seniors paid $3.4 billion in out-of-pocket costs for these drugs in 2022, the CMS stated. 29 August 2023
A new discovery and development collaboration has been agreed between Boston, USA-based Verastem Oncology and Shanghai's GenFleet Therapeutics. 29 August 2023
The European Commission (EC) has approved the extension of the Evrysdi (risdiplam) European Union (EU) marketing authorization to include infants with a clinical diagnosis of spinal muscular atrophy (SMA) type one, type two or type three or with one to four SMN2 copies from birth to below two months. 29 August 2023
Japanese drugmaker Otsuka Holdings subsidiary Taiho Pharmaceutical has entered into an option and license agreement with French biotech firm Phost’in Therapeutics, through which Taiho will gain option rights to in-license PhOx430, a first-in-class small molecule targeting GnT-V (nacetylglucosaminyltransferase-V). 29 August 2023
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.